MTOR and gastric cancer: The unannotated compound in Cluster 1, GSK‐1059615, is identified as a PI3K and MTOR dual inhibitor which, in gastric cancer cells, potently inhibited cell growth, survival, proliferation, and the cell cycle potentially decoupling MYC from its control over cell proliferation [43].